Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: A series of cases

Journal of Clinical Pharmacology

Volumn 45, Issue 6, 2005, Pages 704-708

  García González, Martín J ^a   Domínguez Rodríguez, Alberto ^a   Ferrer Hita, Julio J ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Cardiogenic shock; Levosimendan; Myocardial stunning; ST elevation myocardial infarction (STEMI)

Indexed keywords

CALCIUM SENSITIZER; DIGITALIS; FUROSEMIDE; GLYCERYL TRINITRATE; LEVOSIMENDAN; NITROPRUSSIDE SODIUM;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CONTROLLED STUDY; HEART HEMODYNAMICS; HEART INFARCTION; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; SIDE EFFECT; ST SEGMENT ELEVATION; STUNNED HEART MUSCLE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; ELECTROCARDIOGRAPHY; HUMANS; HYDRAZONES; INTRA-AORTIC BALLOON PUMPING; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL STUNNING; PERICARDITIS; PYRIDAZINES; RESPIRATION, ARTIFICIAL; SHOCK, CARDIOGENIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 18844388165     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004273849     Document Type: Article

References (23)

1. Braunwald E, Kloner RA. The stunned myocardium: prolonged postischemic ventricular dysfunction. Circulation. 1982;66:1146-1149.
2. WJ Remme, K Swedberd, co-chairmen. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology: guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-1560.
3. Manito N, Kaplinsky EJ, Pujol R. Tratamiento inotrópico en la insuficiencia cardíaca: aspectos generales y resultados clínicos. Med Clin (Barc). 2004;122:269-274.
4. Innes CA, Wagstaff AJ. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs. 2003;63:2651-2671.
5. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. Circulation. 2004;110:588-636.
6. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
7. Fargard R, Conway J. Measurement of cardiac output: Fick principle using catheterization. Eur Heart J. 1990;11(suppl I):1-5.
8. Alexander RW, Pratt CM, Ryan TJ, Roberts R. Diagnosis and management of patients with acute myocardial infarction. In: Fuster V, Alexander RW, O'Rourke RA, eds. Hurst's The Heart. 10th ed. New York: McGraw-Hill; 2001:1275-1359.
9. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest. 1975;56:978-985.
10. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999;79:609-634.
11. Haikala H, Pollesello P. Calcium sensitivity enhancers. Idrugs. 2000;3:1199-1205.
12. Rosevear PR, Finley N. Molecular mechanism of levosimendan action: an update. J Mol Cell Cardiol. 2003;35:1011-1015.
13. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilatador with calcium-sensitizing properties. J Cardiovasc Pharmacol. 1998;31:741-749.
14. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903-1912.
15. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med. 1999;341:625-634.
16. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-2147.
17. Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit. 2004;10:89-93.
18. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102:2222-2227.
19. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The Calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43:2177-2182.
20. Poder P, Eha J, Sundberg S, et al. Pharmacodynamics and pharmacokinetics of oral levosimendan and its meabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol. 2004;44:1143-1150.
21. Kivikko M, Antila S, Eha J, Lethonen L, Pentikainen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan and its metabolites, during an extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002;42:43-51.
22. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
23. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAND). Eur Heart J. 2002;23:1422-1432.